ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Comparative Study between ATG and Grafalon as Induction Agent in Renal Transplant Recipient

L. K. Das, P. Paudyal, S. Shrestha, B. Shahi, A. Pandey, R. Verma, P. Chandra Shrestha

Kidney and Liver Transplant, Shahid Dharmabhakta National Transplant Center, Kathmandu, Nepal

Meeting: 2020 American Transplant Congress

Abstract number: A-009

Keywords: Induction therapy, Kidney

Session Information

Date: Saturday, May 30, 2020

Session Name: Poster Session A: Kidney Immunosuppression: Induction Therapy

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

Related Abstracts
  • Combined Antithymocyte Globulin (ATG) and Rituximab (RTX) Induction in African American (AA) Kidney Transplant Recipients
  • Clinical Factors That Determine the More Appropriate Induction Agent: ATG versus IL-2 Receptor Antagonists.

*Purpose: Renal transplantation (Rtx) remains the most effective treatment for of end-stage renal disease (ESRD). The development of induction therapy has significantly reduced the incidence of acute rejection within the first six months following kidney transplantation. As a result, induction therapy is typically administered in the majority of kidney transplants. Moreover, early graft function has also improved with the advent and routine administration of induction therapy. Hence we aim to compare short term outcomes between Rtx patient who got induction by either ATG (anti thymocyte globulin) or Grafalon.

*Methods: We enrolled 40 patient who underwent Rtx for ESRD from Jan 2018 to Feb 2019. We gave each patient induction with either ATG (anti-thymoglobulin) (iATG, n=20) dose of 0.5 mg/kg on operation day followed by 1 mg/kg on POD1 and 2 or another group of patient who got induction by Grafalon (iGF, n=20) with a dose of 6-9 mg/ kg in three divided dose. We compared several 1 month post-transplant outcomes in between two groups and 6 month graft and patient survival.

*Results: We compared several post-transplant outcome variables within 1 month such as infectious complication, acute rejection, antibody mediated rejection, delayed graft function, patient and graft survival. We found that biopsy proven acute tubular necrosis (ATN) was significantly higher in Grafalon group (41.67 % vs 0 %, P= 0.009). Similarly the incidence of culture positive infectious complications were also higher in Grafalon group (30 % vs 10 %, P=0.1). Beside this we did not find any difference between other outcomes as well patient and graft survival.

*Conclusions: Although several polyclonal depleting antibodies are commercially available, ATG remains the most commonly utilized therapeutic induction agent with lower incidence of ATN and infectious complication as shown in our study.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Das LK, Paudyal P, Shrestha S, Shahi B, Pandey A, Verma R, Shrestha PChandra. Comparative Study between ATG and Grafalon as Induction Agent in Renal Transplant Recipient [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/comparative-study-between-atg-and-grafalon-as-induction-agent-in-renal-transplant-recipient/. Accessed March 8, 2021.

« Back to 2020 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Home
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Search
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Home
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.